Executive Management

Isabel Kalofonos serves as Chief Commercial Officer and joined Crinetics in 2024, leading global commercial strategy and operations, as well as pre-commercialization activities for our innovative pipeline of candidates.

She brings more than 22 years of experience leading commercial launches, with expertise across marketing, product planning, market access, and pricing. Prior to Crinetics, she led successful global launch preparations for several major pharmaceutical brands including ELAHERE (mirvetuximab), a treatment for ovarian cancer, as Senior Vice President and Chief Commercial Officer at ImmunoGen/AbbVie, and NEMLUVIO (nemolizumab), a treatment for atopic dermatitis and prurigo nodularis, as Senior Vice President and Global Head of the Prescription Business Unit at Galderma. Isabel also held roles at Takeda Pharmaceuticals (formerly Shire), as Vice President and Head of the Hereditary Angioedema (HAE) franchise, a $2.5-billion business, and gained experience across multiple therapeutic areas, including immunology, rare diseases, oncology, neurology, transplant and gene therapy.

Isabel holds a master’s degree in business administration in entrepreneurship and marketing from Babson College and an undergraduate degree in industrial engineering from Pontificia Universidad Javeriana.